Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer.

Breast Cancer Res · 2024 · PMC10848443 · PMID 38321542

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

Patients with tumors with high HER2/CEP17 ratio levels showed a trend toward worse prognosis as compared to those with intermediate levels (HR = 1.8, CI 1.0–3.2, p = 0.06) and patients with tumors with low levels of HER2/CEP17 ratio had a significantly worse prognosis than those with intermediate levels (HR = 4.8, CI 1.9–12.1, p = 0.0009), (Fig. 3 C, D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.